Fennec Pharmaceuticals (FENC) Return on Capital Employed (2011 - 2026)
Fennec Pharmaceuticals' (FENC) quarterly Return on Capital Employed came in at 12.72% in Q4 2025, down 1843.0% YoY from 0.73% in Q4 2024, and down 1.64% on a QoQ basis from 12.52% in Q3 2025.
Fennec Pharmaceuticals (FENC) Return on Capital Employed (2011 - 2026) Analysis & Trends
Fennec Pharmaceuticals (FENC) has 15 years of Return on Capital Employed data on file, last reported at 12.72% in Q4 2025.
- Quarterly Return on Capital Employed fell 1843.0% year-over-year to 12.72% in Q4 2025, while the trailing twelve-month figure through Dec 2025 was 12.72% (down 1843.0% YoY) and the FY2025 annual result came in at 13.3%, down 2216.0% from the prior year.
- Return on Capital Employed eased to 12.72% in Q4 2025, from 12.52% in the prior quarter.
- In the past five years, Return on Capital Employed ranged from a high of 16.34% in Q1 2024 to a low of 142.25% in Q2 2023.
- A 5-year average of 58.88% and a median of 68.76% in 2021 frame the typical range for Return on Capital Employed.
- Annual changes were most pronounced in 2022 — Return on Capital Employed sank 5171 bps — and 2024, when it soared 15229 bps.
- Tracing FENC's Return on Capital Employed over 5 years: stood at 76.34% in 2021, then dropped by 23 bps to 93.85% in 2022, then rose by 14 bps to 80.48% in 2023, then jumped by 107 bps to 5.7% in 2024, then plunged by 323 bps to 12.72% in 2025.
- The last three Return on Capital Employed figures came in at 12.72% (Q4 2025), 12.52% (Q3 2025), and 25.99% (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 20.76% |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 10.74% |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -55.45% |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 13.68% |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -0.20% |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 7.88% |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 26.09% |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -50.93% |
| 10 | Fennec Pharmaceuticals | 410.60 Mn | 369.35 Mn | 17.15 Mn | -6.15% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -6.15% |
| Dec 31, 2025 | -12.72% |
| Sep 30, 2025 | -12.52% |
| Jun 30, 2025 | -25.99% |
| Mar 31, 2025 | -32.12% |
| Dec 31, 2024 | 5.70% |
| Sep 30, 2024 | 3.14% |
| Jun 30, 2024 | 10.04% |
| Mar 31, 2024 | 16.34% |
| Dec 31, 2023 | -80.48% |
| Sep 30, 2023 | -108.19% |
| Jun 30, 2023 | -142.25% |
| Mar 31, 2023 | -119.42% |
| Dec 31, 2022 | -93.85% |
| Sep 30, 2022 | -102.97% |
| Jun 30, 2022 | -118.25% |
| Mar 31, 2022 | -84.99% |
| Dec 31, 2021 | -76.34% |
| Sep 30, 2021 | -65.32% |
| Jun 30, 2021 | -66.54% |